Perceptive Informatics
Perceptive Informatics is recorded as a service provider in 278 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 278 trials · Latest update first
Phase 2, Open-Label Study in Subjects with Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Sponsor Abbvie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
Operational learnings available5 trial-level findings · Read insights
- The study enrolled 9 participants across France, Israel, Italy, and the Republic of Korea.
- A May 2022 amendment changed the design from a single-arm two-stage study to a single-arm study with two interim analyses.
- Eligibility criteria were updated in amendments dated May 2022 and March 2023.
- A March 2023 amendment updated definitions for time to first deterioration in cough, pain, dyspnea, and physical functioning.
- Paper diary cards were added for sites in China in a March 2023 amendment.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis Followed by a Remission-Withdrawal Period
Sponsor Abbvie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
Operational learnings available6 trial-level findings · Read insights
- The trial had no global interruptions.
- The two independent studies used a common screening platform, and entry into the remission-withdrawal period was optional.
- COVID-19 logistical restrictions accounted for one open-label Study 1 non-completion.
- Geopolitical restrictions accounted for four open-label Study 1 and one open-label Study 2 non-completions.
- A global amendment removed the Japan substudy from Study 1 and revised the number of participating countries to approximately 25.
- MRI eligibility was clarified, and participants with MRI contraindications were excluded.
These findings describe the trial, not the service provider’s performance or responsibility.
Efficacy, safety and pharmacokinetics of cagrilintide s.c. 2.4 mg as monotherapy and in combination with semaglutide s.c. 2.4 mg (CagriSema) once weekly for weight management in children and adolescents with overweight or obesity
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Study of Elironrasib (RMC-6291), With or Without Daraxonrasib (RMC-6236), in Combination With Other Anti-Cancer Agents, in Patients With RAS G12C-Mutated Non-Small Cell Lung Cancer – Subprotocol A
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicentre, Open-label, Randomised, Phase IV Study to Investigate Acalabrutinib Monotherapy Compared to Investigator’s Choice of Treatment in Adults (> 18 Years) With Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012).
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects with Idiopathic Pulmonary Fibrosis
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multi-Site, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of eRapa to Improve Clinical Outcomes in Participants with Familial Adenomatous Polyposis
Sponsor Biodexa Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia
Sponsor BeOne Medicines I GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living with Overweight or Obesity without Diabetes (RISE-1)
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma
Sponsor Revolution Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN SICKLE CELL DISEASE (SCD)
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- Participants were recruited at 26 investigative sites across 11 countries from 09 March 2022 to 09 April 2026.
- One participant was randomized in error, was not treated, and was excluded from the presented results.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination with BNT116 (FixVac Lung) versus Cemiplimab Monotherapy in First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with Tumors Expressing PD-L1 ≥50%
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination with Chemotherapy versus Cemiplimab in Combination with Chemotherapy in Patients with Resectable Early Stage (Stage II to IIIB [N2]) NSCLC
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sponsor Calico Life Sciences LLC
- Start (EU)
- Latest update
- Estimated end
An Open-Label Study of Mibavademab (REGN4461), a Leptin Receptor Agonist, for the Treatment of Monogenic Obesity Due to Biallelic Loss of Function Variants of the LEP Gene
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
An Open-label, Multinational Study Assessing the Efficacy and Safety of Dato-DXd Treatment in Patients With HR-positive, HER2 IHC 0, Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy (TROPION-Breast06)
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Perceptive Informatics?
The 2026-10-09 snapshot links Perceptive Informatics to 278 distinct CTIS trials. Recorded services include Interactive response technology (IRT), Imaging, Medical image analysis/ review - X-ray, MRI, ultrasound, etc., Central imaging, among 108 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Perceptive Informatics?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Haematological Malignancies, Respiratory, Gastroenterology. Recorded phases include Phase 3, Phase 2, Phase 1, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Perceptive Informatics conducted?
The linked trials record locations in 26 countries, including Spain, France, Italy, Germany, Poland. These are trial locations, not confirmed office locations or countries where Perceptive Informatics delivered services.
What can this page tell me about Perceptive Informatics's trial experience?
Browse 278 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 8 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Perceptive Informatics. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Perceptive Informatics Inc.
- Perceptive Informatics, LLC